Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | LY3076226 |
| Synonyms | |
| Therapy Description |
LY3076226 is comprised of an FGFR3-directed monoclonal antibody conjugated to a toxic compound, which may result in death of FGFR3-expressing tumor cells (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| LY3076226 | LY-3076226 | FGFR3 Antibody 5 | LY3076226 is comprised of an FGFR3-directed monoclonal antibody conjugated to a toxic compound, which may result in death of FGFR3-expressing tumor cells (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT02529553 | Phase I | LY3076226 | A Study of LY3076226 in Participants With Advanced or Metastatic Cancer | Completed | USA | CAN | 0 |